TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17514726

Group type: EXPERIMENTAL
Intervention: Supplementary breaks (two 15 min breaks plus four 5 min breaks per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Stretching exercises during breaks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional breaks (two 15 min breaks per day)
Number of subjects: 51
Study: 15087592

Group type: EXPERIMENTAL
Intervention: Shower PUVA with trioxsalen (0.27 mg/l) for 10 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Shower PUVA with trioxsalen (0.27 mg/l) for 5 min
Number of subjects: 20
Study: 12409965

Group type: EXPERIMENTAL
Intervention: Orlistat plus diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 0
Study: 9855321

Group type: EXPERIMENTAL
Intervention: valspodar 400 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: both drugs concomitantly
Number of subjects: 18
Study: 7738215

Group type: EXPERIMENTAL
Intervention: Intermittent famotidine (20 mg every 12 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous infusion of cimetidine (1200 mg/24 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous infusion of ranitidine (150 mg/24 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous infusion of famotidine (40 mg/24 hr)
Number of subjects: 6
Study: 2973343

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dacron
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 80
Study: 4925077

Group type: EXPERIMENTAL
Intervention: 5% idoxuridine in dimethyl sulphoxide intermittently applied
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40% idoxuridine in dimethyl sulphoxide continuously applied for four days
Number of subjects: 0
Study: 31797570

Group type: EXPERIMENTAL
Intervention: Generic prucalopride tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Test formulation (generic)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation (branded)
Number of subjects: 12
Study: 31256911

Group type: EXPERIMENTAL
Intervention: Cephalomedullary nail (Targon® PF or PFT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sliding hip screw (SHS)
Number of subjects: 1000
Study: 27422781

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (ClosureFAST™)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endovenous laser ablation (980 nm diode laser)
Number of subjects: 200
Study: 25782717

Group type: EXPERIMENTAL
Intervention: Fluoxetine (9 week open label trial)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Eszopiclone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23577643

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Sitagliptin (Sita)
Number of subjects: 458
Study: 21689394

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (10-14 sessions: 6-10 during pregnancy and 4-8 after delivery)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 300
Study: 19690254

Group type: EXPERIMENTAL
Intervention: Guidewire
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Slit endotracheal tube
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neck flexion with lateral neck pressure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 16796078

Group type: EXPERIMENTAL
Intervention: Fenofibrate 130 mg/day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 15648529

Group type: EXPERIMENTAL
Intervention: Parent Management Treatment (PMT) in the experimental group (E)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Not applicable (control group untreated)
Number of subjects: 238
Study: 11259986

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily for 8 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Simvastatin 40 mg once daily alone
Number of subjects: 18
Study: 9426081

Group type: EXPERIMENTAL
Intervention: Salbutamol 2x100 microg via Turbuhaler
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg via Turbuhaler
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Salbutamol 50 microg via Turbuhaler
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg via pMDI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Salbutamol 2x200 microg via pMDI
Number of subjects: 62

Group type: COMPARATOR
Intervention: Salbutamol via Turbuhaler vs pMDI
Number of subjects: 62
Study: 8513955

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (200 mg) under fasting conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100, 200, or 300 mg) under fasting conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (200 mg) under nonfasting conditions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intramuscular progesterone (50 mg in oil)
Number of subjects: 15
Study: 3103158

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10 mg/kg caffeine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28652090

Group type: EXPERIMENTAL
Intervention: PCPs aware of USPSTF recommendations for LDCT
Number of subjects: 250
Study: 27486873

Group type: EXPERIMENTAL
Intervention: Deferasirox treatment (mean daily dose 11.8 ± 7.0 mg/kg, mean duration 16 months)
Number of subjects: 99
Study: 24529600

Group type: EXPERIMENTAL
Intervention: NeuroFlo treatment
Number of subjects: 0
Study: 22219335

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg twice daily for 1 week)
Number of subjects: 13
Study: 19473822

Group type: EXPERIMENTAL
Intervention: Cheese naturally rich in cis-9, trans-11 CLA (200 g/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Commercially available cheese (placebo)
Number of subjects: 10
Study: 18693230

Group type: EXPERIMENTAL
Intervention: In-home intervention involving occupational and physical therapy home instruction in problem solving, device use, energy conservation, safety, fall recovery, balance, and muscle strengthening.
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: In-home intervention
Number of subjects: 319
Study: 15897376

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conservative acne therapy
Number of subjects: 132
Study: 12849654

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 222

Group type: COMPARATOR
Intervention: Class I agents
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 222
Study: 12675021

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day for 3 years)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Alendronate (any dose)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study: 8947071

Group type: EXPERIMENTAL
Intervention: Low frequency breathing (LFB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 1782518

Group type: EXPERIMENTAL
Intervention: Table-top simulation, photographs of road situations, real-world sites near schools
Number of subjects: 0
Study: 7272178

Group type: EXPERIMENTAL
Intervention: Caroxazone 200 mg three times daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caroxazone (after discontinuation)
Number of subjects: 9
Study: 31513968

Group type: EXPERIMENTAL
Intervention: Syndromal anxious depression
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: HRSD anxious depression
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study: 31036468

Group type: EXPERIMENTAL
Intervention: Tucidinostat plus exemestane
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 365
Study: 28017254

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 26313348

Group type: EXPERIMENTAL
Intervention: nano-calcium phosphate paste
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 24140678

Group type: EXPERIMENTAL
Intervention: Prasugrel with low-dose aspirin (<150 mg)
Number of subjects: 12674

Group type: EXPERIMENTAL
Intervention: Prasugrel with high-dose aspirin (≥150 mg)
Number of subjects: 12674

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 12674
Study: 21884007

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: B-group vitamins (folic acid 1 mg, vitamin B12 0.4 mg, and B6 10 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rosuvastatin and B-group vitamins combined
Number of subjects: 36
Study: 19538242

Group type: COMPARATOR
Intervention: Metformin 1 g orally with a standard mixed meal (SMM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin 1 g orally without a SMM (fasting)
Number of subjects: 10
Study: 18085140

Group type: EXPERIMENTAL
Intervention: Medicine cup group (n = 47) treated with cupping therapy using a self-made medicine cup with 45 degrees C Chinese herb solution.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Water cup group (n = 47) treated with a cup with 45 degrees C water.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Empty cup group (n = 46) treated with a cup with nothing.
Number of subjects: 140
Study: 15318859

Group type: EXPERIMENTAL
Intervention: Accepted donors (Group A)
Number of subjects: 4158

Group type: COMPARATOR
Intervention: Deferred donors (Group B)
Number of subjects: 4158
Study: 15505358

Group type: EXPERIMENTAL
Intervention: AngioJet rheolytic thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional primary angioplasty
Number of subjects: 0
Study: 10598600

Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 100% O2 (group SevoRAPID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2%, 4%, 6%, and 7% sevoflurane in 100% O2 (group SevoINCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1%, 2%, 3%, and 3.5% halothane in 50% N2O‐50% O2 (group HaloN2O)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 50% N2O‐50% O2 (group SevoN2O)
Number of subjects: 0
Study: 8528851

Group type: EXPERIMENTAL
Intervention: Rapid i.v. injection of famotidine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Slow i.v. infusion of famotidine
Number of subjects: 105
Study: 1778319

Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccine (25 micrograms PT)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccine (8 micrograms PT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Whole-cell DTP vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccines (both doses)
Number of subjects: 2
Study: 7213528

Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aminophylline (390 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg) administered intravenously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg) administered intravenously
Number of subjects: 14
Study: 30776016

Group type: EXPERIMENTAL
Intervention: Contemporary dance practice (2 hours per week for 5 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Contemporary dance practice
Number of subjects: 19
Study: 28485186

Group type: EXPERIMENTAL
Intervention: Daclizumab beta
Number of subjects: 1841

Group type: COMPARATOR
Intervention: IM interferon beta-1a
Number of subjects: 1841
Study: 26994623

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.05%) plus intranasal steroid (budesonide 100 μg/spray)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25180876

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg twice a day for 2 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 22056021

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1121
Study: 21123578

Group type: EXPERIMENTAL
Intervention: High threat condition (potentially harmful)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low threat condition (entirely safe)
Number of subjects: 0
Study: 17613279

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, orally twice daily with meals for one month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard therapeutic regimen)
Number of subjects: 60
Study: 15701354

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist condition (WL)
Number of subjects: 20
Study: 12005153

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 33
Study: 9790395

Group type: EXPERIMENTAL
Intervention: 400 microg rectal misoprostol
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study: 8538974

Group type: EXPERIMENTAL
Intervention: Telephone support intervention (weekly calls throughout pregnancy)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no telephone support)
Number of subjects: 131
Study: 31867655

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes (0.4, 2.4, 5.2, 15.8 mg/g)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes
Number of subjects: 169
Study: 30287158

Group type: EXPERIMENTAL
Intervention: Sertraline and olanzapine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 57
Study: 26162521

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TG) 80 mg daily for 4 days
Number of subjects: 10
Study: 24284442

Group type: EXPERIMENTAL
Intervention: W25 (25 g whey protein, 3.0 g leucine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: W6 (6.25 g whey protein, 0.75 g leucine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: W6+Low‐Leu (6.25 g whey protein supplemented to 3.0 g total leucine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: W6+High‐Leu (6.25 g whey protein supplemented to 5.0 g total leucine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BCAAs (6.25 g whey protein supplemented with leucine, isoleucine, and valine to 5.0 g total leucine)
Number of subjects: 40
Study: 22871086

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium 0.3 mg intravitreal injection
Number of subjects: 1586
Study: 18823228

Group type: EXPERIMENTAL
Intervention: Tryptophan supplements (3 g per day for 14 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 15
Study: 17893438

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/ml, maximum 16 mg) in a single dose
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hydrocortisone (8‐10 mg/kg/day) in 4 equal doses for 2 days
Number of subjects: 47
Study: 15502721

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 11684376

Group type: EXPERIMENTAL
Intervention: Transdermal continuous hormonal replacement therapy (HRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9596459

Group type: EXPERIMENTAL
Intervention: Diagnosis of otitis media (OM) by physicians
Number of subjects: 21259

Group type: EXPERIMENTAL
Intervention: Diagnosis of upper respiratory infections (URI) by physicians
Number of subjects: 21259
Study: 7888289

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for 8 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin (0.1 mg ml-1) in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin (small concentrations up to 0.19 micrograms ml-1) in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin (higher concentrations) in vitro
Number of subjects: 0
Study: 3285878

Group type: EXPERIMENTAL
Intervention: Nifedipine 120 mg/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 29119833

Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 0
Study: 28537581

Group type: EXPERIMENTAL
Intervention: Probiotic (5x10^9 colony‐forming units)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 25380149

Group type: EXPERIMENTAL
Intervention: perindopril/amlodipine
Number of subjects: 1757

Group type: COMPARATOR
Intervention: valsartan/amlodipine
Number of subjects: 1757
Study: 23158043

Group type: EXPERIMENTAL
Intervention: Shoulder surgeons evaluating full-thickness tears of the supraspinatus central tendon on MRI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Shoulder surgeons vs MSK radiologists evaluating full-thickness tears of the supraspinatus central tendon on MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shoulder surgeons evaluating partial-thickness tears of the supraspinatus central tendon on MRI
Number of subjects: 40
Study: 20197560

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography after unloading manipulations
Number of subjects: 43

Group type: COMPARATOR
Intervention: Swan-Ganz catheterization
Number of subjects: 43
Study: 18759767

Group type: EXPERIMENTAL
Intervention: PARMA 5 computer-assisted dosage
Number of subjects: 10421

Group type: COMPARATOR
Intervention: Manual dosage by experienced medical staff
Number of subjects: 10421
Study: 16176613

Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Casein (placebo)
Number of subjects: 43
Study: 12732395

Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 43
Study: 10372217

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 32
Study: 9082342

Group type: EXPERIMENTAL
Intervention: Heterozygous carriers for Leiden mutation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients with idiopathic thromboembolic disease
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 2069221

Group type: EXPERIMENTAL
Intervention: Isotonic saline flush once a week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin flush twice daily
Number of subjects: 0
Study: 6429407

Group type: EXPERIMENTAL
Intervention: Nutritional therapy with an EAA mixture containing tyrosine, increased valine, and decreased leucine proportions compared to normal recommendations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplementation with valine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with EAA mixture.
Number of subjects: 0
Study: 31666828

Group type: EXPERIMENTAL
Intervention: Neostigmine (1 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (35 μg [0.5 μg/kg])
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of Neostigmine (0.5 mg) and Dexmedetomidine (35 μg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (Lidocaine 1.5% + Triamcinolone 40 mg/ml)
Number of subjects: 33
Study: 29892252

Group type: COMPARATOR
Intervention: three funny things intervention (humor-based PPI)
Number of subjects: 736

Group type: COMPARATOR
Intervention: five different humor-based interventions
Number of subjects: 736

Group type: COMPARATOR
Intervention: three funny things intervention
Number of subjects: 736

Group type: COMPARATOR
Intervention: humor-based interventions
Number of subjects: 736
Study: 27348904

Group type: EXPERIMENTAL
Intervention: Acupoint embedding therapy applied to Ganshu (BL 18), Tai‐chong (LR 3), Fenglong (ST 40), Zusanli (ST 36), and Sanyinjiao (SP 6), once every 7 days for 6 months.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acupoint embedding therapy group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine capsules (essentiale), 228 mg/capsule, 2 capsules three times a day for 6 months.
Number of subjects: 180
Study: 25089880

Group type: EXPERIMENTAL
Intervention: AP-training group (action preferences training)
Number of subjects: 2

Group type: COMPARATOR
Intervention: NP-training group (no action preferences training)
Number of subjects: 2
Study: 22914550

Group type: EXPERIMENTAL
Intervention: Phase advanced misalignment (3 × 21 h)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phase delayed misalignment (3 × 27 h)
Number of subjects: 13
Study: 20159428

Group type: COMPARATOR
Intervention: Topiramate 100 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate 50 mg/day
Number of subjects: 0
Study: 17950182

Group type: EXPERIMENTAL
Intervention: Facial massage (20 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Foot massage (20 min)
Number of subjects: 6
Study: 15019896

Group type: EXPERIMENTAL
Intervention: Elevated pulse pressure (PP)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Low pulse pressure (PP)
Number of subjects: 489
Study: 11799759

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole‐trimethoprim (SXT) prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontyphoidal salmonellae sensitivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shigellae sensitivity
Number of subjects: 0
Study: 9923576

Group type: EXPERIMENTAL
Intervention: Oral contraceptive formulation containing 2 mg dienogest and 0.03 mg ethinylestradiol (group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral contraceptive formulation containing 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol (group B)
Number of subjects: 23
Study: 7848003

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 168